{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094886","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2026-08-12T20:14:40+00:00","discovered_at":"2026-08-12T20:16:01.785454+00:00","generated_at":"2026-08-12T20:16:25.944600+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MaxCyte Q2 revenue $7.3M, down 15% YoY; net loss narrows; Genentech partnership signed","bullets":["Q2 2026 total revenue $7.3M, down 15% YoY; core revenue $6.5M (-21%), SPL revenue $0.8M.","Net loss $8.9M vs $12.4M loss in Q2 2025; operating expenses down to $15.8M.","Cash and investments $141.9M at June 30, 2026; repurchased ~$5.5M under $10M program.","Reiterates FY2026 guidance: revenue $30-32M (core $25-27M, SPL ~$5M); cash ≥$130.5M.","In July 2026 signed first multi-platform technology license partnership with Genentech."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094886","json":"https://secwatch.observer/filing/0001104659-26-094886.json","markdown":"https://secwatch.observer/filing/0001104659-26-094886.md","text":"https://secwatch.observer/filing/0001104659-26-094886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/0001104659-26-094886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/mxct-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:16:25.944600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}